Denali Therapeutics IncDNLI
ASignal's systematic analysis rates DNLI as Neutral.
Reflects the latest available analysis · analyzed Aug 29, 2026
The case on DNLI
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong financial health score (0.9)
- Low debt-to-equity ratio (0.05x)
- High cash position ($710.47M cash vs $37.69M debt)
- High liquidity with current ratio of 8.37x
- RSI near neutral (42.4), not overbought
- Negative price momentum (-1.44%)
- MACD below signal line, indicating bearish momentum
- Negative operating and net margins (operating margin: -3601.30%, net margin: 0.00%)
- Negative return on equity (-54.93%) and return on assets (-29.15%)
- Extremely high valuation metrics (P/S: 1064.47x, EV/Revenue: 907.51x)
- No Reddit mentions, indicating low retail interest or visibility
See the full verdict on DNLI
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes DNLI
Most investors never get a second opinion, let alone several. ASignal runs DNLI past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.